Iovance Biotherapeutics Inc (NASDAQ:IOVA) – Stock analysts at Jefferies Group issued their Q1 2018 EPS estimates for shares of Iovance Biotherapeutics in a research note issued to investors on Monday. Jefferies Group analyst B. Amin forecasts that the biotechnology company will post earnings per share of ($0.30) for the quarter. Jefferies Group currently has a “Buy” rating and a $31.00 target price on the stock. Jefferies Group also issued estimates for Iovance Biotherapeutics’ Q2 2018 earnings at ($0.30) EPS, Q4 2018 earnings at ($0.31) EPS and FY2022 earnings at $1.60 EPS.

How to Become a New Pot Stock Millionaire

A number of other brokerages have also commented on IOVA. BidaskClub lowered Iovance Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 22nd. ValuEngine upgraded Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. HC Wainwright upped their target price on Iovance Biotherapeutics from $16.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, January 25th. Oppenheimer upped their target price on Iovance Biotherapeutics from $13.00 to $19.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. Finally, Zacks Investment Research upgraded Iovance Biotherapeutics from a “hold” rating to a “buy” rating and set a $10.00 target price on the stock in a research report on Wednesday, January 17th. Three analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $19.72.

Shares of Iovance Biotherapeutics (IOVA) opened at $17.20 on Wednesday. The company has a market capitalization of $1,460.00, a P/E ratio of -12.20 and a beta of 5.91. Iovance Biotherapeutics has a 52-week low of $4.45 and a 52-week high of $19.90.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its earnings results on Monday, March 12th. The biotechnology company reported ($0.36) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.04).

A number of institutional investors have recently added to or reduced their stakes in the business. Orbimed Advisors LLC boosted its position in Iovance Biotherapeutics by 89.9% in the 3rd quarter. Orbimed Advisors LLC now owns 6,425,626 shares of the biotechnology company’s stock worth $49,799,000 after purchasing an additional 3,042,726 shares in the last quarter. BlackRock Inc. boosted its position in Iovance Biotherapeutics by 9.0% in the 4th quarter. BlackRock Inc. now owns 4,864,841 shares of the biotechnology company’s stock worth $38,918,000 after purchasing an additional 401,743 shares in the last quarter. Perceptive Advisors LLC boosted its position in Iovance Biotherapeutics by 1.1% in the 4th quarter. Perceptive Advisors LLC now owns 4,776,114 shares of the biotechnology company’s stock worth $38,208,000 after purchasing an additional 50,000 shares in the last quarter. Vanguard Group Inc. purchased a new stake in Iovance Biotherapeutics in the 2nd quarter worth approximately $16,113,000. Finally, Farallon Capital Management LLC boosted its position in Iovance Biotherapeutics by 119.6% in the 4th quarter. Farallon Capital Management LLC now owns 1,866,900 shares of the biotechnology company’s stock worth $14,935,000 after purchasing an additional 1,016,900 shares in the last quarter. Institutional investors and hedge funds own 67.82% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was published by Daily Political and is owned by of Daily Political. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this article can be viewed at https://www.dailypolitical.com/2018/03/14/research-analysts-set-expectations-for-iovance-biotherapeutics-incs-q1-2018-earnings-iova.html.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.

Earnings History and Estimates for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.